Dose escalation of Fractionated Stereotactic Radiotherapy (FSRT) for brain metastases from non-small cell lung cancer: protocol of a phase I study
Research Square
2023
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Background About half of lung cancer patients are found to have brain metastasis during the course of the disease. Fractionated stereotactic radiotherapy (FSRT) is a reliable treatment for patients with localized brain metastases. However, there is currently controversy over the prescription doses of FSRT. The aim of this study is to determine maximum tolerated dose of FSRT for brain metastasis from non-small cell lung cancer. Methods This study is a prospective mono-center phase I dose escalation trial which will recruit patients with brain metastases from non-small cell lung cancer receiving FSRT in 5 fractions. A standard 3 + 3 statistical design was employed. The dose escalation consists of 7 cohorts. FSRT will starting at 6 Gy × 5 fractions (dose level 1). The highest dose level will be 10 Gy × 5 fractions. The primary objective of this study is to determine the maximum tolerated dose. Secondary outcomes include acute and late toxicities following FSRT, intracranial progression-free survival (iPFS) and overall survival (OS). Discussion Since the prescription dose of FSRT treatment for patients with localized brain metastases are still unknow, we conducted a Phase I study to determine the maximum tolerated dose of FSRT for limited brain metastases. This trial protocol has been approved by the Ethics committee of Hangzhou cancer hospital. The ethics number is HZCH-2022 #124. This study was registered at ClinicalTrials.gov on 10/20/2022 (NCT05588206).
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know